Hepatocyte cell therapy in liver disease

被引:16
作者
Bartlett, David Christopher [1 ]
Newsome, Philip N.
机构
[1] Univ Birmingham, NIHR Ctr Liver Res, Birmingham, W Midlands, England
基金
英国医学研究理事会;
关键词
acute liver failure; bioartificial liver device; cell therapy; hepatocyte cell therapy; hepatocyte transplantation; inborn errors of metabolism; liver failure; HEMATOPOIETIC STEM-CELLS; FULMINANT HEPATIC-FAILURE; BIOARTIFICIAL LIVER; N-ACETYLCYSTEINE; GENE-THERAPY; CHARCOAL HEMOPERFUSION; PREPARATIVE REGIMEN; METABOLIC DISEASES; ASSIST DEVICE; PHASE-I;
D O I
10.1586/17474124.2015.1073106
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Liver disease is a leading cause of morbidity and mortality. Liver transplantation remains the only proven treatment for end-stage liver failure but is limited by the availability of donor organs. Hepatocyte cell therapy, either with bioartificial liver devices or hepatocyte transplantation, may help address this by delaying or preventing liver transplantation. Early clinical studies have shown promising results, however in most cases, the benefit has been short lived and so further research into these therapies is required. Alternative sources of hepatocytes, including stem cell-derived hepatocytes, are being investigated as the isolation of primary human hepatocytes is limited by the same shortage of donor organs. This review summarises the current clinical experience of hepatocyte cell therapy together with an overview of possible alternative sources of hepatocytes. Current and future areas for research that might lead towards the realisation of the full potential of hepatocyte cell therapy are discussed.
引用
收藏
页码:1261 / 1272
页数:12
相关论文
共 124 条
[61]  
Mullon C, 1999, Expert Opin Investig Drugs, V8, P229, DOI 10.1517/13543784.8.3.229
[62]   Treatment of cirrhosis and liver failure in rats by hepatocyte xenotransplantation [J].
Nagata, H ;
Ito, M ;
Cai, J ;
Edge, AS ;
Platt, JL ;
Fox, IJ .
GASTROENTEROLOGY, 2003, 124 (02) :422-431
[63]   Serum from patients with fulminant hepatic failure causes hepatocyte detachment and apoptosis by a β1-integrin pathway [J].
Newsome, PN ;
Tsiaoussis, J ;
Masson, S ;
Buttery, R ;
Livingston, C ;
Ansell, I ;
Ross, JA ;
Sethi, T ;
Hayes, PC ;
Plevris, JN .
HEPATOLOGY, 2004, 40 (03) :636-645
[64]   Liver gene therapy: advances and hurdles [J].
Nguyen, TH ;
Ferry, N .
GENE THERAPY, 2004, 11 (Suppl 1) :S76-S84
[65]   Ex Vivo Liver-Directed Gene Therapy for the Treatment of Metabolic Diseases: Advances in Hepatocyte Transplantation and Retroviral Vectors [J].
Nguyen, Tuan Huy ;
Mainot, Sylvie ;
Lainas, Panagiotis ;
Groyer-Picard, Marie-Therese ;
Franco, Dominique ;
Dagher, Ibrahim ;
Weber, Anne .
CURRENT GENE THERAPY, 2009, 9 (02) :136-149
[66]  
NHS Blood and Transplant, 2011, TRANSPL ACT UK
[67]   Tumorigenesis in cells derived from induced pluripotent stem cells [J].
Nishimori, Makoto ;
Yakushiji, Hiromasa ;
Mori, Michihiro ;
Miyamoto, Tomoyuki ;
Yaguchi, Takahiro ;
Ohno, Setsuyo ;
Miyake, Yasuyuki ;
Sakaguchi, Takuya ;
Ueda, Masatsugu ;
Ohno, Eiji .
HUMAN CELL, 2014, 27 (01) :29-35
[68]   EVOLUTION OF THE BIOARTIFICIAL LIVER - THE NEED FOR RANDOMIZED CLINICAL-TRIALS [J].
NYBERG, SL ;
PESHWA, MV ;
PAYNE, WD ;
HU, WS ;
CERRA, FB .
AMERICAN JOURNAL OF SURGERY, 1993, 166 (05) :512-521
[69]   Stem cells, cell transplantation and liver repopulation [J].
Oertel, Michael ;
Shafritz, David A. .
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE, 2008, 1782 (02) :61-74
[70]  
OGRADY JG, 1993, LANCET, V342, P273